10.7150/thno.14556 Summary Keywords hyaluronic acid, breast cancer, anticancer drugs, nanoparticles, drug delivery system (DDS) Citation Jia Y, Chen S, Wang C, Sun T and Yang L (2022) Hyaluronic acid-based nano drug delivery systems for breast cancer treatment: Recent advances
When a protocol says "inject 0.25 mg weekly," it is referring to the weight of the drug itself, not the volume of liquid and not the markings on your syringe
Vaccination: HBV vaccine Vaccine Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases
Long-Term Considerations and Discontinuing GLP-1 Agonists Hannah : One common concern with GLP-1 agonists is maintaining weight loss after stopping the medication
Bjerre Knudsen et al., 2010
The amylin receptor agonist class represents a complementary mechanism of action that may synergize with GLP-1 agonism
